Anglonordic Life Science Conference XII

Transcription

1 improving nature s own defense mechanisms Anglonordic Life Science Conference XII London, April 23rd

2 Lytix Biopharma AS Norwegian non-listed company Founded 2003 Tromsø Technology platform- de novo designed host defence peptides LTX-315 oncolytic peptide immunotherapy LTX-109 topical antimicrobial peptide Oslo

3 Lytix Biopharma cancer immunotherapy focused Strategy Discover and develop drug candidates to phase II With partner for late stage development and commercialization Lead Product The opportunity Evidence Team Potential first-in-class oncolytic peptide immunotherapy LTX-315, induces the release of potent immune stimulants and an extended range of patients` own tumor antigens increase patient specific immune response to attack cancer Multi-indication potential for transdermally accessible tumors Targeting melanoma as first indication Ideal combination partner for immune checkpoint inhibitors through complementary mode of action Strong pre-clinical and promising clinical Phase I data Extensive experience from drug development, business development and commercialization of oncology products

4 Complementary Modes of Action - LTX-315 and immune checkpoint inhibitors are ideal combination partners Checkpoint inhibitors - allow T-cells access to tumor cells Oncolytic immune stimulants - induce a specific immune response Yervoy (BMS) 2011 Keytruda (MSD) 2014 Opdivo (BMS) 2014 plus others in development Patient s own tumor antigens & immunostimulants Oncolytic peptide LTX-315 (Lytix) Oncolytic viruses T-VEC (Amgen) Oncos-102 (Oncos) Checkpoint Inhibitors Break tolerance T-Cells allow T-cells to attack cancer Tumor Oncolysis LTX-315 Cancer attacked by increased quantity of T-cells

5 Effect on injected and non-injected lesions 2 nd tumor 3 rd tumor Control v 1st 3 rd 2 nd LTX-315 v Days LTX-315 induces systemic tumor specific immune responses

6 LTX-315 induces tumor specific immune response in cancer patients Complete and partial regression of injected lesions Baseline After treatment Infiltration of Cytotoxic CD8 + T-cells in injected lesions Before: Few CD8 + T-cells After treatment: Increase of CD8 + T-cells LTX-315 has a predictable and mild safety profile

7 Management Unni Hjelmaas CEO Extensive pharma industry senior leadership experience, national and international oncology strategy, marketing and life cycle management experience - former General Manager for Roche Norway Co-Chairman of the Board of the Norwegian Pharma Industry Association and member of the board of Oslo Cancer Cluster Andrew Saunders CMO Extensive experience in all aspects and phases of heamato-oncology drug development from both clinical practice and industry Prior to Lytix - founded and acted as Managing Director of Linden Oncology Limited, a consultancy providing strategic and clinical development haemato-oncology expertise to biotech and pharmaceutical companies globally Wenche Marie Olsen, DrPhilos COO Extensive senior leadership experience within research, development and management of new drug products in pharmaceutical and biotech industry Former CEO of Lauras, various positions in Nycomed/GE Healthcare Øystein Rekdal, PhD Co-founder and CSO Oncology Former CEO of Lytix Biopharma (from establishment in 2003) Extensive research background, and professor in the Medical Biochemistry Department in the Faculty of Medicine at the University of Tromsø John S. Svendsen, PhD Co-founder and Head of Exploratory Research Extensive research experience, and professor of organic chemistry at the University of Tromsø Visiting scientist at several distinguished international institutions, including the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at MIT Håkan Wickholm Head of Business Development and Commercialisation Extensive senior management and leadership experience from AstraZeneca Experience from both sell- and buy-side, from search, through assessments, evaluations, due diligence and negotiations to closure of deals Henning Mork CFO Broad and senior level background from finance, business development and general management. Previous experience from listed and non-listed companies within financial management, funding, legal, logistics and commercialization

8 LTX-315 adresses unmet medical need and presents a commercial opportunity Potential to enhance clinical benefit in combination with conventional cancer treatment, including immune checkpoint inhibitors, through complementary mode of action and a mild and predictable safety profile Multi-indication potential for transdermally accessible cancers Target melanoma as first indication

9